CN102603862B - Finasteride purification method - Google Patents
Finasteride purification method Download PDFInfo
- Publication number
- CN102603862B CN102603862B CN 201210050341 CN201210050341A CN102603862B CN 102603862 B CN102603862 B CN 102603862B CN 201210050341 CN201210050341 CN 201210050341 CN 201210050341 A CN201210050341 A CN 201210050341A CN 102603862 B CN102603862 B CN 102603862B
- Authority
- CN
- China
- Prior art keywords
- finasteride
- product
- filtrate
- water
- purification method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention discloses a finasteride purification method which comprises the following steps of: dissolving crude finasteride into a methanol-formic acid solution; adding active carbon and stirring for 2-3 hours; filtering and flushing the filtrate with water to obtain a white precipitate; and collecting the white material and drying under reduced pressure to obtain a high-purity finasteride product. Compared with the prior art, the method has the advantages of being simple, quick and efficient and being low in cost.
Description
Technical field
The present invention relates to a kind of purification process of chemicals, specifically, is a kind of purification process of finasteride.
Background technology
Finasteride, English name: Finasteride, chemical name: the N-tertiary butyl-3-carbonyl-4-azepine-5 alpha-androstane-1-alkene-17 β-acid amides.Finasteride is a kind of 4-aza steroid, and it is the specific inhibitor that the testosterone metabolism becomes desmo enzyme in the stronger dihydrotestosterone process-II type 5a-reductase enzyme.And benign prostatic hyperplasia or be called prostatomegaly and depend on that testosterone is to the conversion of dihydrotestosterone in the prostate gland.This medicine can reduce blood and intraprostatic dihydrotestosterone very effectively, alleviate weight of prostate, increase the urine flow rate, urinary tract obstruction and complication are improved significantly, the prostate gland symptoms integration is obviously descended, be applicable to treatment Symptomatic benign prostate hyperplasia (BPH).At present, the patent of relevant finasteride and documents and materials such as US4760071, US20060046994, US5547957, US5981543, EP0599376, US2886184, US567043, CN1718586, J Med Chem 1984,27,1690-1701, the punching of the purification process of reporting such as dissolve with methanol-water is analysed, re-crystallizing in ethyl acetate, purification yield is low generally speaking for finasteride that ethyl acetate-methods such as Iso Butyl Acetate recrystallization obtain, and purity is difficult to the European Pharmacopoeia standard-required that reaches higher.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of simple, fast and efficient finasteride purification process.
In order to address the above problem, the technical solution adopted in the present invention is:
With the finasteride dissolving crude product in methyl alcohol-formic acid mixing solutions, and after adding the activated carbon stirring, filter, add large water gaging punching in the filtrate and analyse, produce a large amount of white precipitates this moment, filter and collect white depositions, analyze our surprised discovery by HPLC behind the drying under reduced pressure, its purity HPLC＞99.7%, total assorted＜0.3%, list mixes＜0.1%, calculates the gained purifying rate of recovery＞96% according to the thick product of input finasteride.
The ratio of above-mentioned methyl alcohol and formic acid is by volume: 0.5-3: 1, and optimum is: 1: 1.
The consumption of above-mentioned activated carbon is counted by finasteride: 0.05-0.2eq.
Above-mentioned churning time is 1-5h, and optimum is 3h.
Consumption and methyl alcohol-formic acid solution volume ratio that middle water is analysed in above-mentioned filtrate water punching are 2-20: 1, and optimum is 10: 1.
Beneficial effect: report in the relative document patent of the present invention as with behind the dissolve with methanol again water punching analyse, the method for re-crystallizing in ethyl acetate, this method can obtain the very high finasteride product of purity, and purification yield is high, simple, quick, efficient.
Embodiment
The purifying of 1 finasteride
Finasteride crude product 10g (HPLC=98.0% always mixes 2.0%, maximum single assorted 0.6%) is dissolved in methyl alcohol-formic acid solution of 1: 1 of 50ml, and then after adding 1g activated carbon stirring 3h, filter, filtrate is analysed with the punching of 500ml water, separate out a large amount of white solids, suction filtration collecting precipitation thing, drying under reduced pressure namely get finasteride product 9.7g, the rate of recovery 97%, HPLC＞99.7%, always mix＜0.3%, single assorted＜0.1%, mp=255.5-257 ℃.
2 dissolve with methanol-water rushes analysis method purifying finasteride
With finasteride crude product 10g (HPLC=98.0%, always assorted 2.0%, maximum single assorted 0.6%) stirring and dissolving in 50ml methyl alcohol, filter, filtrate is analysed with the punching of 500ml water, separates out a large amount of white solids, suction filtration collecting precipitation thing, drying under reduced pressure namely gets finasteride product 9.0g, the rate of recovery 90%, HPLC=98.7% always mixes 1.3%, maximum single assorted 0.31%, mp=255-257 ℃.
3 re-crystallizing in ethyl acetate method purifying finasterides
With finasteride crude product 10g (HPLC=98.0%, always assorted 2.0%, maximum single assorted 0.6%) heating for dissolving in ethyl acetate, decolorizing with activated carbon, heat filtering, a large amount of white solids, suction filtration collecting precipitation thing are separated out in the filtrate cooling, drying under reduced pressure namely gets finasteride product 8.1g, the rate of recovery 81%, HPLC＞98.8% always mixes 1.2%, maximum single assorted 0.35%, mp=255-257 ℃.
4 ethyl acetate-Iso Butyl Acetate recrystallization method purifying finasteride
With finasteride crude product 10g (HPLC=98.0%, total assorted 2.0%, maximum single assorted 0.6%) heating for dissolving is in ethyl acetate-Iso Butyl Acetate solution, heat filtering, a large amount of white solids are separated out in the filtrate cooling, suction filtration collecting precipitation thing, drying under reduced pressure namely get finasteride product 8.3g, the rate of recovery 83%, HPLC＞98.9%, always mix 1.1%, maximum single assorted 0.3%, mp=255-257 ℃.
5 formic acid activated carbon method purifying finasterides
Finasteride crude product 10g (HPLC=98.0% always mixes 2.0%, maximum single assorted 0.6%) is dissolved in the 30ml formic acid solution, and then after adding 1g activated carbon stirring 3h, filter, filtrate is analysed with the punching of 500ml water, separate out a large amount of white solids, suction filtration collecting precipitation thing, drying under reduced pressure namely get finasteride product 9.7g, the rate of recovery 97%, HPLC＞99.3%, always mix 0.7%, maximum single assorted＞0.2%, mp=255-257 ℃.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210050341 CN102603862B (en) | 2012-02-29 | 2012-02-29 | Finasteride purification method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210050341 CN102603862B (en) | 2012-02-29 | 2012-02-29 | Finasteride purification method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102603862A CN102603862A (en) | 2012-07-25 |
| CN102603862B true CN102603862B (en) | 2013-09-18 |
Family
ID=46521683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210050341 Expired - Fee Related CN102603862B (en) | 2012-02-29 | 2012-02-29 | Finasteride purification method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102603862B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395466B (en) * | 2018-01-12 | 2020-11-10 | 天方药业有限公司 | Recrystallization method for improving purity of finasteride |
| CN111484542B (en) * | 2020-04-30 | 2024-01-30 | 湖北葛店人福药业有限责任公司 | Treatment method of finasteride mother liquor |
| CN114213502B (en) * | 2021-12-08 | 2024-02-13 | 湖南醇健制药科技有限公司 | Method for refining finasteride, finasteride preparation and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
| CN1718586A (en) * | 2005-06-09 | 2006-01-11 | 武汉大学 | Synthetic method of N-tert-butyl-3-carbonyl-4-aza-5α-androst-1-ene-17β-carboxamide |
| US20070167477A1 (en) * | 2006-01-13 | 2007-07-19 | Mandava Venkata Naga Brahmeswa | Processes to prepare finasteride polymorphs |
| CN101531698A (en) * | 2009-04-08 | 2009-09-16 | 重庆浩康医药化工有限公司 | Synthesis technology of finasteride |
-
2012
- 2012-02-29 CN CN 201210050341 patent/CN102603862B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
| CN1718586A (en) * | 2005-06-09 | 2006-01-11 | 武汉大学 | Synthetic method of N-tert-butyl-3-carbonyl-4-aza-5α-androst-1-ene-17β-carboxamide |
| US20070167477A1 (en) * | 2006-01-13 | 2007-07-19 | Mandava Venkata Naga Brahmeswa | Processes to prepare finasteride polymorphs |
| CN101531698A (en) * | 2009-04-08 | 2009-09-16 | 重庆浩康医药化工有限公司 | Synthesis technology of finasteride |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102603862A (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102603862B (en) | Finasteride purification method | |
| CN104693260B (en) | A kind of processing method of dehydroepiandrosterone mother liquor | |
| CN105085373B (en) | Purification method of apremilast product | |
| CN106883281A (en) | The method that chenodeoxycholic acid is extracted from duck bile | |
| WO2021012673A1 (en) | Method for preparing trenbolone acetate | |
| KR20250023544A (en) | Production process and device for continuously producing 5-hydroxymethyl furfural | |
| CN101215311B (en) | Method for producing ursodesoxycholic acid from 86% of chenodeoxycholic acid | |
| CN108138210B (en) | Method for selectively preparing ginsenoside Rd from ginsenoside by enzymatic method | |
| CN102617374A (en) | Method for preparing betaine hydrochloride | |
| CN104557576B (en) | A kind of preparation method of high-purity Pregabalin | |
| CN101456897B (en) | Method for preparing 3-carbonyl-4-aza-5alpha-androstanes | |
| CN108864240B (en) | Method for purifying dexamethasone epoxy hydrolysate | |
| CN103059096A (en) | Synthesis method of deflazacort intermediate with [17a,16a-d] oxazoline structure | |
| CN110746415A (en) | Synthesis process for continuously preparing azilsartan under microchannel reactor | |
| CN102146113B (en) | Method for synthesizing 16 alpha-hydroxy prednisolone | |
| CN110563787B (en) | A preparation method of 5α-androsterone-17-hydroxy-3-ketone | |
| CN103274923A (en) | Method for recycling dehydropregnenolone acetate waste liquor | |
| CN109422642A (en) | Refining methd, the production method and equipment of pharmaceutical grade sodium benzoate of benzoic acid | |
| CN109503691A (en) | A kind of synthetic method of 5 α-androstane -3,17- diketone | |
| WO2023126014A1 (en) | Estrone synthesis method | |
| CN101565379B (en) | The preparation method of L-homoserine hydrochloride | |
| CN101974064A (en) | Method for synthesizing crataegolic acid | |
| CN100395262C (en) | A kind of production method of betulin | |
| CN103864632A (en) | Production method for glycine ethyl ester hydrochloride | |
| CN111484542B (en) | Treatment method of finasteride mother liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20150229 |
|
| EXPY | Termination of patent right or utility model |